ArticleKidney international reports2026
Phenotypic Spectrum of HNF4α-Associated Fanconi Renotubular Syndrome.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Fanconi renal tubular syndrome 4 (FRTS4) is a very rare, autosomal dominant disease caused by heterozygous variants affecting the arginine residue at position 85 of the Methods: We conducted an international, physician-based, anonymous data collection within the European Rare Kidney Disease Reference Network and beyond, focusing on clinical features, treatment, and the progression of chronic kidney disease (CKD) in patients with FRTS4. Results: Overall, we collected data on 25 patients. Twenty-four of these carried the classic p.R85W variant, and 1 carried a new p.R85L variant. Prematurity and macrosomia at birth were frequently observed. Congenital hyperinsulinism with postnatal hypoglycemia was documented in 14 of 21 patients. Renal Fanconi syndrome was diagnosed at a median age of 1.5 (interquartile range: 0.1-4.3) years. Common symptoms included failure to thrive (13/23), rickets (9/25), nephrocalcinosis (12/25), and CKD before age 10 years (13/19). All tested patients exhibited low-molecular-weight proteinuria, aminoaciduria, and glycosuria. Hyperphosphaturia, metabolic acidosis, and hypercalciuria were present in most patients. The main extrarenal symptoms were liver abnormalities and cardiac septal defects. During a median follow-up period of 8.1 years kidney function deteriorated slowly. All adult patients progressed to CKD stage 3. Four patients developed maturity-onset diabetes of the young (MODY). Conclusion: These findings provide a comprehensive picture of FRTS4. The disease should be suspected in children presenting with renal Fanconi syndrome, especially if there was fetal macrosomia and if they have experienced neonatal hypoglycemia. Progression of CKD is invariably observed, and liver and cardiac involvement should always be investigated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.